

Supplementary Table 5. Prescribed medications by age, gender, demographic characteristics, and health conditions

	Age group					Gender		Cirrhosis status		DAA exposure status		p value	
	18-34 years	35-44 years	45-54 years	55-64 years	65-74 years	≥ 75 years	Male	Female	Without Cirrhosis	With Cirrhosis	Unexposed		Exposed
Total													
Total hepatitis C infected patients	1,405 (2.8)	3,474 (6.9)	11,312 (22.4)	15,536 (30.80)	11,402 (22.6)	7,347 (14.6)	23,592 (46.7)	26,884 (53.3)	47,850 (94.8)	2,626 (5.2)	27,232 (54.0)	23,244 (46.0)	- ^{a)}
Patient with ≥ 1 prescribed medication	1,315 (93.6)	3,360 (96.7)	11,092 (98.1)	15,380 (99.90)	11,363 (99.7)	7,336 (99.9)	23,236 (98.5)	26,610 (99.9)	47,231 (98.7)	2,615 (99.6)	26,856 (98.6)	22,990 (98.9)	- ^{a)}
Mean number of medications	9.5	6.2	7.6	8.5	9.3	10.4	9.2	9.7	9.4	10.9	9.4	9.5	- ^{a)}
Comedications													
Analgesics	45,669 (91.6)	1,123 (85.4)	9,878 (89.1)	14,053 (91.4)	10,689 (94.1)	6,986 (95.2)	20,900 (89.9)	24,769 (93.1)	43,270 (91.6)	2,399 (91.4)	24,613 (91.6)	21,056 (91.6)	< 0.0001
Gastrointestinal agents	42,347 (85.0)	955 (72.6)	9,018 (81.3)	13,111 (85.2)	10,042 (88.4)	6,580 (89.7)	19,140 (82.4)	23,207 (87.2)	40,031 (84.8)	2,316 (88.2)	22,866 (85.1)	19,481 (84.7)	< 0.0001
Antibacterials	40,013 (80.3)	1,032 (78.5)	8,574 (77.3)	12,236 (79.6)	9,421 (82.9)	6,127 (83.5)	18,075 (77.8)	21,938 (82.4)	37,851 (80.1)	2,162 (82.3)	21,591 (80.4)	18,422 (80.1)	< 0.0001
Antihistamines	36,644 (73.5)	873 (66.4)	7,615 (68.7)	11,163 (72.6)	8,863 (78.0)	5,778 (78.8)	16,219 (69.8)	20,425 (76.8)	34,649 (73.4)	1,995 (76.0)	19,715 (73.4)	16,929 (73.6)	< 0.0001
Anticoagulant, anti-platelet and fibrinolytic	30,987 (62.2)	699 (53.2)	1,925 (58.7)	9,510 (61.8)	7,532 (66.3)	4,809 (65.6)	13,946 (60.0)	17,041 (64.0)	29,395 (62.2)	1,592 (60.6)	16,812 (62.6)	14,175 (61.7)	< 0.0001
Steroids	29,152 (58.5)	651 (49.5)	1,743 (51.9)	9,038 (58.8)	7,138 (62.8)	4,555 (62.1)	12,586 (54.2)	16,566 (62.3)	27,605 (58.4)	1,547 (58.9)	15,704 (58.5)	13,448 (58.5)	< 0.0001
Antiarrhythmics	24,748 (49.6)	380 (28.9)	1,123 (43.4)	7,716 (50.2)	6,540 (57.6)	4,171 (56.9)	11,479 (49.4)	13,269 (49.9)	23,318 (49.4)	1,430 (54.5)	13,331 (49.6)	11,417 (49.7)	< 0.0001
Anxiolytics/hypnotics/sedatives	21,737 (43.6)	265 (20.2)	1,136 (33.8)	6,763 (44.0)	5,376 (47.3)	3,783 (51.6)	9,525 (41.0)	12,212 (45.9)	20,369 (43.1)	1,368 (52.1)	11,762 (43.8)	9,975 (43.4)	< 0.0001
Herbals/supplements/vitamins	21,475 (43.1)	266 (20.2)	1,050 (31.3)	6,419 (41.7)	5,370 (47.3)	4,064 (55.4)	10,220 (44.0)	11,255 (42.3)	19,896 (42.1)	1,579 (60.1)	11,588 (43.1)	9,887 (43.0)	< 0.0001
Hepatotonics	19,302 (38.7)	257 (19.5)	998 (29.7)	5,783 (37.6)	4,398 (38.7)	3,672 (50.1)	10,386 (44.7)	8,916 (33.5)	17,415 (36.9)	1,887 (71.9)	10,597 (39.5)	8,705 (37.9)	< 0.0001
Hypertension/heart failure agents	18,692 (37.5)	43 (3.3)	416 (12.4)	5,371 (34.9)	5,626 (49.5)	4,518 (61.6)	9,072 (39.0)	9,620 (36.2)	17,262 (36.5)	1,430 (54.5)	10,004 (37.3)	8,688 (37.3)	< 0.0001

Supplementary Table 5. Continued

	Total	Age group						Gender		Cirrhosis status		DAA exposure status		p value
		18-34 years	35-44 years	45-54 years	55-64 years	65-74 years	≥ 75 years	Male	Female	Without Cirrhosis	With Cirrhosis	Unexposed	Exposed	
Calcium channel blockers	14,586 (29.3)	35 (2.7)	311 (9.3)	1,989 (17.9)	4,160 (27.0)	4,446 (39.1)	3,645 (49.7)	7,125 (30.7)	7,461 (28.0)	13,652 (28.9)	934 (35.6)	7,812 (29.1)	6,774 (29.5)	< 0.0001
Lipid lowering agents	14,200 (28.5)	53 (4.0)	389 (11.6)	2,229 (20.1)	4,575 (29.7)	4,195 (36.9)	2,759 (37.6)	6,354 (27.3)	7,846 (29.5)	13,528 (28.6)	672 (25.6)	8,418 (31.3)	5,782 (25.2)	< 0.0001
Antidiabetics	9,496 (19.1)	26 (2.0)	238 (7.1)	1,686 (15.2)	2,865 (18.6)	2,744 (24.1)	1,937 (26.4)	5,409 (23.3)	4,087 (15.4)	8,698 (18.4)	798 (30.4)	4,911 (18.3)	4,585 (19.9)	0.0008
Antidepressants	9,412 (18.9)	122 (9.3)	474 (14.1)	1,913 (17.2)	2,777 (18.1)	2,275 (20.0)	1,851 (25.2)	4,044 (17.4)	5,368 (20.2)	8,823 (18.7)	589 (22.4)	5,074 (18.9)	4,338 (18.9)	< 0.0001
Beta blockers	8,576 (17.2)	64 (4.9)	315 (9.4)	1,311 (11.8)	2,404 (15.6)	2,431 (21.4)	2,051 (28.0)	4,124 (17.7)	4,452 (16.7)	7,838 (16.6)	738 (28.1)	4,618 (17.2)	3,958 (17.2)	< 0.0001
Bronchodilators	8,311 (16.7)	166 (12.6)	504 (15.0)	1,369 (12.3)	2,473 (16.1)	2,144 (18.9)	1,655 (22.6)	3,599 (15.5)	4,712 (17.7)	7,868 (16.7)	443 (16.9)	4,557 (17.0)	3,754 (16.3)	< 0.0001
Anesthetics and muscle relaxants	7,818 (15.7)	133 (10.1)	487 (14.5)	1,590 (14.3)	2,438 (15.9)	1,939 (17.1)	1,231 (16.8)	3,594 (15.5)	4,224 (15.9)	7,364 (15.6)	454 (17.3)	4,218 (15.7)	3,600 (15.7)	< 0.0001
Antifungals	7,671 (15.4)	263 (20.0)	743 (22.1)	1,891 (17.0)	2,230 (14.5)	1,601 (14.1)	943 (12.9)	2,787 (12.0)	4,884 (18.4)	7,325 (15.5)	346 (13.2)	4,194 (15.6)	3,477 (15.1)	< 0.0001
Anticonvulsants	7,386 (14.8)	63 (4.8)	311 (9.3)	1,472 (13.3)	2,140 (13.9)	1,921 (16.9)	1,479 (20.2)	3,473 (14.9)	3,91 (14.7)	6,91 (14.6)	475 (18.1)	3,911 (14.6)	3,475 (15.1)	< 0.0001

Values are presented as number (%).

DAA, direct-acting antiviral.

^ap value not provided.